HALO News & Events

Halozyme (HALO) announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (VRTX). Under the collaboration, Vertex has licensed Halozyme's Hypercon technology for use in up to three drug targets. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration. Under the terms of the exclusive agreement, Vertex will make a $15M upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon technology.

Halozyme announced that David Ramsay has been appointed Interim CFO, effective March 23. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up. He previously served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company.